Specific genotyping will be performed in all hrHPV positive samples. DNA extracted will be genotyped. In all HPV positive self-collected samples the investigators will perform quantitative methylation analyses in order to obtain a quantification for the methylation status of the investigated CpGs, using DNA extracted for genotyping. The investigators will evaluate Methylation of CpG islands within promoter regions of genes and microRNAs such as CADM1 (Cell adhesion molecule 1), MAL (Myelin and lymphocyte protein), and hsa-miR-124- and methylation status of the HPV regions L1 and L2. The investigators will investigate for each type the CpGs located nearby the sequence position of HPV16 CpGs which have been highlighted as associated with an increased risk of cervical intraepithelial neoplastic (CIN2+) disease: L1 nucleotide positions 5601-5616 and 6457; L2 nucleotide position 4261.